These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 30388256)

  • 61. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
    Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
    Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women.
    Limsui D; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Harnack LJ; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
    Gut; 2012 Sep; 61(9):1299-305. PubMed ID: 22027477
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular Subtypes Are Frequently Discordant Between Lesions in Patients With Synchronous Colorectal Cancer: Molecular Analysis of 59 Patients.
    Arakawa K; Hata K; Nozawa H; Kawai K; Tanaka T; Nishikawa T; Sasaki K; Shuno Y; Kaneko M; Hiyoshi M; Emoto S; Murono K; Sonoda H; Okada S; Ishihara S
    Anticancer Res; 2019 Mar; 39(3):1425-1432. PubMed ID: 30842178
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.
    Kambara T; Simms LA; Whitehall VL; Spring KJ; Wynter CV; Walsh MD; Barker MA; Arnold S; McGivern A; Matsubara N; Tanaka N; Higuchi T; Young J; Jass JR; Leggett BA
    Gut; 2004 Aug; 53(8):1137-44. PubMed ID: 15247181
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Methylator phenotype in colorectal cancer: A prognostic factor or not?
    Gallois C; Laurent-Puig P; Taieb J
    Crit Rev Oncol Hematol; 2016 Mar; 99():74-80. PubMed ID: 26702883
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
    Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
    Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Left-sided early-onset vs late-onset colorectal carcinoma: histologic, clinical, and molecular differences.
    Pilozzi E; Maresca C; Duranti E; Giustiniani MC; Catalanotto C; Lucarelli M; Cogoni C; Ferri M; Ruco L; Zardo G
    Am J Clin Pathol; 2015 Mar; 143(3):374-84. PubMed ID: 25696795
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serrated polyposis associated with a family history of colorectal cancer and/or polyps: The preferential location of polyps in the colon and rectum defines two molecular entities.
    Silva P; Albuquerque C; Lage P; Fontes V; Fonseca R; Vitoriano I; Filipe B; Rodrigues P; Moita S; Ferreira S; Sousa R; Claro I; Nobre Leitão C; Chaves P; Dias Pereira A
    Int J Mol Med; 2016 Sep; 38(3):687-702. PubMed ID: 27430658
    [TBL] [Abstract][Full Text] [Related]  

  • 71. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
    de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
    Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer.
    Sideris M; Papagrigoriadis S
    Anticancer Res; 2014 May; 34(5):2061-8. PubMed ID: 24778007
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Healthy and unhealthy plant-based diets in relation to the incidence of colorectal cancer overall and by molecular subtypes.
    Wang F; Ugai T; Haruki K; Wan Y; Akimoto N; Arima K; Zhong R; Twombly TS; Wu K; Yin K; Chan AT; Giannakis M; Nowak JA; Meyerhardt JA; Liang L; Song M; Smith-Warner SA; Zhang X; Giovannucci EL; Willett WC; Ogino S
    Clin Transl Med; 2022 Aug; 12(8):e893. PubMed ID: 35998061
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer.
    Slattery ML; Curtin K; Sweeney C; Levin TR; Potter J; Wolff RK; Albertsen H; Samowitz WS
    Int J Cancer; 2007 Feb; 120(3):656-63. PubMed ID: 17096326
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma.
    Siraj AK; Bu R; Prabhakaran S; Bavi P; Beg S; Al Hazmi M; Al-Rasheed M; Alobaisi K; Al-Dayel F; AlManea H; Al-Sanea N; Uddin S; Al-Kuraya KS
    Mol Cancer; 2014 Jul; 13():168. PubMed ID: 25005754
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort.
    Chen KH; Lin LI; Yuan CT; Tseng LH; Chao YL; Liang YH; Liang JT; Lin BR; Cheng AL; Yeh KH
    Br J Cancer; 2021 Jul; 125(1):48-54. PubMed ID: 33846524
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Methylation in p14(ARF) is frequently observed in colorectal cancer with low-level microsatellite instability.
    Kominami K; Nagasaka T; Cullings HM; Hoshizima N; Sasamoto H; Young J; Leggett BA; Tanaka N; Matsubara N
    J Int Med Res; 2009; 37(4):1038-45. PubMed ID: 19761686
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
    Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
    Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.